The FDA is removing black box warnings on hormone treatments, marking a pivotal shift in regulatory policy. This change emphasizes the therapeutic benefits of hormones, notably the protective effects of estrogen against hearing loss and the reduced clotting risks associated with transdermal estrogen versus oral formulations. This decision, which also acknowledges testosterone's performance-enhancing properties, indicates a significant transformation in healthcare approaches to hormone therapy.
